查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014932

肺動脈支架市場：2026年至2032年全球市場預測（依產品類型、適應症、材料、病患年齡層及通路分類）

Lung Stents Market by Product Type, Indication, Material, Patient Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肺支架市場價值將達到 1.3335 億美元，到 2026 年將成長至 1.4598 億美元，到 2032 年將達到 2.3523 億美元，年複合成長率為 8.44%。

主要市場統計數據
基準年 2025 1.3335億美元
預計年份：2026年 1.4598億美元
預測年份 2032 2.3523億美元
複合年成長率 (%) 8.44%

這篇前瞻性的介紹概述了臨床需求、材料創新和醫療保健系統獎勵如何相互交織，從而重塑肺支架的開發和臨床應用。

肺支架可用於治療多種氣道疾病，從良性結構脆弱到惡性阻塞，並且與微創介入和個體化呼吸護理等更廣泛的趨勢日益契合。臨床醫生正在採用更精密的器材設計來適應氣管和支氣管複雜的解剖結構，而工程師則應用先進的材料科學和製造技術來改善支架的輸送、徑向力分佈和生物相容性。同時，保險公司和醫療保健系統優先考慮能夠減少重症監護使用和再入院的治療效果，從而獎勵採用持久可靠的干涉措施，以縮短康復時間並提高生活品質。

本文簡要概述了正在重新定義整個肺支架生態系統競爭優勢和臨床預期的關鍵技術、監管和供應鏈變化。

肺支架領域正經歷一場變革，材料科學、手術影像技術和病患選擇的進步正在改變氣道植入的設計標準和臨床預期。新型材料，例如生物可吸收聚合物和鎂基支架，旨在最大限度地減少長期異物暴露，同時提供臨時的結構支撐，這些選擇使得人們對與組織癒合過程相契合的器械越來越感興趣。同時，內視鏡視覺化、3D氣道建模以及植入系統的改進，正在提升治療解剖結構複雜病變的能力，使其更加精準，並降低圍手術全期風險。

分析性回顧 2025 年美國關稅改革將如何改變整個肺支架價值鏈的採購經濟、製造地策略和商業合約。

美國於2025年實施的關稅調整對整個肺支架供應鏈產生了連鎖反應。這反映出該產業對貿易政策的敏感性，無論是在原料採購或成品分銷方面。某些進口零件關稅的提高立即導致依賴全球供應商的製造商的總交付成本上升，迫使採購團隊重新評估籌資策略和總交付成本的計算方法。為此，一些製造商加快了更接近終端市場的供應商認證計劃，並探索能夠在保持臨床性能的同時降低受貿易關稅波動影響的替代原料。

多層次細分分析揭示了產品類型、臨床適應症、材料科學、患者人口統計特徵和分銷管道如何驅動不同的開發和商業化需求。

細分市場的發展趨勢揭示了清晰的發展軌跡和臨床應用案例，這些因素持續影響產品藍圖和商業化策略。按產品類型分類，市場包括生物可吸收支架、藥物釋放型支架、金屬支架和聚合物支架。生物可吸收支架進一步細分為鎂基支架和聚乳酸（PLLA）基支架，而聚合物支架則分為可生物分解型和不可生物分解型。這些產品差異會影響臨床決策，例如支架的耐久性、發炎反應以及後續干預的必要性，並指導研發重點，例如最佳化徑向支撐強度、控制吸收曲線以及最佳化輸送系統的人體工學設計。從器械配置到臨床應用，基於適應症的細分包括氣道阻塞、軟化症、氣管支氣管狹窄和腫瘤相關應用，其中腫瘤適應症進一步細分為良性和惡性亞型。每項適應症都有其獨特的程序挑戰和監管證據要求，因此需要製定適當的研究設計和差異化的上市後監測計畫。

對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐、監管複雜性和採購重點進行精細的區域評估，從而確定部署路徑。

區域趨勢帶來了獨特的臨床、監管和商業性優先事項，這些優先事項會影響醫療設備製造商和服務供應商的策略規劃。在美洲，醫療保健系統越來越重視能夠證明治療效果和長期安全性的證據，同時供應鏈的韌性和本土製造能力也影響採購決策。這些因素推動了對擁有廣泛臨床註冊數據和可預測服務模式的醫療設備的需求。相較之下，歐洲、中東和非洲地區的市場環境複雜多元，法規結構和報銷夥伴關係各不相同，因此需要採取適應性強的打入市場策略。製造商通常會尋求有針對性的核准，並建立當地合作夥伴關係，以應對分散的健康技術評估 (HTA) 流程和多樣化的臨床實踐模式。

公司層面的關鍵見解強調了臨床證據、卓越製造、智慧財產權和夥伴關係在確定肺支架領域的競爭地位的重要性。

主要企業之間的競爭格局聚焦於透過技術創新、臨床證據的累積以及旨在加速產品准入和醫保報銷的策略聯盟來實現差異化。市場領導正大力投資於器械的迭代改進，力求在多個司法管轄區獲得監管核准，同時建立註冊登記系統和開展上市後研究，以展現其產品性能的對比優勢。同時，中小創新者正透過開發專用支架和新型藥物釋放型平台，開拓細分市場，並經常與大型製造商建立銷售和聯合開發夥伴關係，以擴大高效的商業化規模。智慧財產權組合仍然是至關重要的資產，保護構成臨床差異化基礎的關鍵材料配方、支架結構和遞送機制的專利策略至關重要。

為協調產品開發、證據計畫、供應鏈韌性和商業模式，以加速臨床引進和市場進入，提出切實可行的策略建議。

產業領導企業應採取整合策略，協調產品創新、證據產生和供應鏈韌性，以有效掌握臨床和商業性機會。首先，應優先考慮使材料選擇和器械結構與明確定義的適應症和患者群體相匹配的研發路徑，從而降低監管複雜性並促進臨床醫生採納。同時，應投資於早期且持續的真實世界數據（REW）項目，以補充主要臨床試驗，因為持續的結局數據收集有助於加強醫保報銷談判並支持器械的迭代改進。此外，加強與策略供應商的關係並實現製造地多元化，可以降低關稅和物流風險，同時加快對臨床需求的反應速度。

我們採用了一種透明的混合方法研究途徑，結合專家訪談、文件分析和資料三角驗證，以檢驗臨床、技術和商業性見解，並找出證據差距。

本分析所依據的研究採用了一種混合方法，結合了初步的定性研究和嚴謹的二手文獻綜述，以確保對臨床、技術和商業性方面有全面的了解。初步研究包括對介入手術專家、胸腔外科醫師、醫療設備開發人員、採購負責人和監管專家進行結構化訪談，以收集關於手術需求、材料性能和採購標準的第一手觀點。基於這些見解，研究人員提出了假設，並透過對臨床文獻、醫療設備註冊資訊、監管申報文件和技術評​​估報告的系統性回顧檢驗了這些假設，從而支持了利益相關人員訪談中提出的安全性和性能主題。

結論強調，綜合證據的建立、製造韌性和協作商業模式將決定肺支架應用的未來方向。

肺支架領域正處於一個轉折點，材料創新、手術流程進步以及採購趨勢的演變都在影響哪些技術將在臨床實踐中廣泛應用。將設計改進轉化為可衡量的患者獲益，需要協調投資於臨床證據、生產可靠性和上市後結果收集。此外，近期政策的變化和供應鏈壓力凸顯了多元化採購和監管靈活性在業務營運中的關鍵作用。在相關人員應對這些複雜挑戰的過程中，能夠整合嚴謹的臨床數據產生、高度靈活的生產製造和精準的商業策略的機構，將更有利於實現永續的臨床價值和機構發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：肺動脈支架市場：依產品類型分類

  • 生物可吸收支架
    • 鎂基
    • PLLA集團
  • 藥物釋放型支架
  • 金屬支架
  • 聚合物支架
    • 可生物分解
    • 不可生物分解

第9章：肺動脈支架市場：依適應症分類

  • 氣道阻塞
  • 氣管軟化症
  • 支氣管狹窄
  • 瘤
    • 良性腫瘤
    • 惡性腫瘤

第10章：肺動脈支架市場：依材料分類

  • 鎳鈦諾
  • 聚合物基
    • 聚左旋乳酸
    • 聚碳酸酯胺甲酸乙酯
  • 不銹鋼

第11章：依患者年齡層分類的肺動脈支架市場

  • 成人版
  • 老年人
  • 兒童

第12章：肺動脈支架市場：依通路分類

  • 門診手術中心
  • 診所
  • 醫院

第13章：肺動脈支架市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：肺動脈支架市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：肺動脈支架市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國肺動脈支架市場

第17章：中國肺支架市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Boston Scientific Corporation
  • BVM Medical Limited
  • Cook Medical LLC
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd
  • Merit Medical Systems, Inc.
  • Novatech SA
  • Stening SRL
  • Taewoong Medical Co., Ltd
  • WL Gore & Associates, Inc.
Product Code: MRR-437A5D08AE43

The Lung Stents Market was valued at USD 133.35 million in 2025 and is projected to grow to USD 145.98 million in 2026, with a CAGR of 8.44%, reaching USD 235.23 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 133.35 million
Estimated Year [2026] USD 145.98 million
Forecast Year [2032] USD 235.23 million
CAGR (%) 8.44%

A forward-looking introduction that frames how clinical demand, materials innovation, and health system incentives converge to reshape lung stent development and clinical adoption

Lung stents address a spectrum of airway pathologies that range from benign structural weakness to malignant obstruction, and they increasingly intersect with broader trends in minimally invasive intervention and personalized respiratory care. Clinicians are adopting more sophisticated device designs to manage complex tracheobronchial anatomies, while engineers apply advanced materials science and manufacturing techniques to improve deliverability, radial force profiles, and biocompatibility. At the same time, payers and health systems emphasize outcomes that reduce intensive care utilization and rehospitalization, thereby creating incentives for durable, reliable interventions that shorten recovery and improve quality of life.

Consequently, the landscape for lung stents is evolving along multiple axes: clinical demand driven by aging populations and expanded indications; technical innovation encompassing novel alloys, polymer chemistries, and drug elution strategies; and commercial pressures that reward devices demonstrating clear procedural efficiencies and long-term safety. These converging factors have heightened the importance of robust clinical evidence, reproducible manufacturing quality, and post-market surveillance. As a result, stakeholders must integrate cross-functional perspectives-from interventional pulmonology and thoracic surgery to regulatory affairs and supply chain management-to navigate adoption pathways and realize the potential patient benefits of next-generation lung stents.

A concise synthesis of pivotal technological, regulatory, and supply chain shifts that are redefining competitive advantages and clinical expectations across the lung stent ecosystem

The lung stent landscape is experiencing transformative shifts as advances in materials science, procedural imaging, and patient selection converge to change both the design criteria and clinical expectations for airway implants. Newer materials such as bioresorbable polymers and magnesium-based scaffolds aim to minimize long-term foreign body exposure while providing temporary structural support, and these options have catalyzed interest in devices that align with tissue healing trajectories. Simultaneously, improvements in endoscopic visualization, three-dimensional airway modeling, and deployment systems have expanded the ability to treat anatomically complex lesions with greater precision and lower perioperative risk.

Moreover, the regulatory and reimbursement environment is evolving in parallel, with authorities increasingly demanding real-world evidence and robust post-approval monitoring to validate safety profiles outside controlled trials. As a consequence, manufacturers are investing in registry infrastructure and digital health integrations to capture outcomes continuously. In addition, supply chain resilience and manufacturing scalability have risen as strategic priorities after recent global disruptions, prompting onshoring initiatives and closer supplier partnerships. Together, these shifts are not incremental but structural: they redefine competitive advantages toward organizations that can combine clinical evidence generation, advanced materials engineering, and agile commercialization strategies to meet the new standard of care.

An analytical review of how United States tariff reforms in 2025 altered sourcing economics, manufacturing location strategy, and commercial contracting across the lung stent value chain

The United States tariff adjustments enacted in 2025 have produced cascading effects across the lung stent supply chain, reflecting the industry's sensitivity to trade policy on both raw material inputs and finished device flows. Increased tariffs on select imported components raised immediate landed costs for manufacturers reliant on global suppliers, prompting procurement teams to reassess sourcing strategies and total landed cost calculations. In response, some producers accelerated supplier qualification programs closer to end markets and explored alternative inputs that preserve clinical performance while reducing exposure to volatile trade fees.

In addition, tariffs influenced capital deployment decisions, as manufacturers weighed the economics of incremental onshore capacity investments against continued reliance on international partners. This rebalancing often extended product lead times in the near term while creating opportunities for localized manufacturing partnerships that prioritize time-to-clinic and responsiveness to customer demand. Clinicians and hospital purchasers felt these changes indirectly through contracting cycles and inventory strategies, leading many health systems to prefer suppliers with diversified manufacturing footprints that could mitigate tariff-driven supply disruptions.

Furthermore, the policy environment shaped commercial negotiations and pricing dynamics, with payers and group purchasing organizations seeking greater transparency on cost drivers and clinical value. As transitional effects rippled through the ecosystem, companies that communicated clear supply continuity plans and maintained robust quality systems experienced stronger procurement relationships. Looking ahead, the tariff episode underscored the strategic importance of supply chain flexibility, regulatory harmonization across jurisdictions, and the capacity to justify material substitutions through clinical and bench data to preserve patient safety while controlling costs.

A multilayered segmentation analysis revealing how product type, clinical indication, material science, patient demographics, and distribution channels drive distinct development and commercialization imperatives

Segment-level dynamics reveal distinct development trajectories and clinical use-cases that continue to shape product road maps and commercialization strategies. Based on product type, the market includes bioresorbable stents, drug-eluting stents, metallic stents, and polymer stents, with bioresorbable options further differentiated into magnesium-based and PLLA-based designs and polymer stents categorized into biodegradable and nondegradable variants. These product distinctions influence clinical decision-making around durability, inflammatory response, and the need for subsequent interventions, and they guide R&D priorities toward optimizing radial strength, controlled resorption profiles, and delivery system ergonomics. Transitioning from device composition to clinical application, the indication-based segmentation captures airway obstruction, malacia, tracheobronchial stenosis, and tumor-related uses, with tumor indications further divided into benign and malignant subtypes. Each indication presents unique procedural challenges and regulatory evidence expectations, prompting tailored trial designs and differentiated post-market surveillance plans.

Material choice further intersects with performance objectives, with options spanning nitinol, polymer-based constructs, and stainless steel; polymer-based materials are further subdivided into poly-L-lactic acid and polycarbonate urethane variants that each bring different mechanical and biocompatibility profiles. These material-level trade-offs factor into both clinician preference and manufacturing complexity, affecting sterilization protocols and shelf-life considerations. Patient age group segmentation also merits attention, as adults, geriatric patients, and pediatric populations demand different sizing, flexibility, and long-term safety profiles, thereby influencing labeling strategies and pediatric study commitments. Finally, distribution channel segmentation across ambulatory surgical centers, clinics, and hospitals shapes go-to-market approaches, service models, and training programs; ambulatory settings often prioritize streamlined inventory and rapid turnover, whereas hospital systems emphasize full-service support, robust clinical training, and integration with multidisciplinary airway teams. Taken together, these granular segmentation insights highlight how developers and commercial teams must align product design, clinical evidence, and channel strategy to match the nuanced needs encountered across practice settings and patient groups.

A nuanced regional assessment of clinical practices, regulatory complexity, and procurement priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption pathways

Regional dynamics impose distinct clinical, regulatory, and commercial priorities that influence strategic planning for device manufacturers and service providers. In the Americas, health systems emphasize evidence demonstrating procedural efficiency and long-term safety, while supply chain resilience and domestic manufacturing increasingly shape procurement decisions; these factors drive demand for devices supported by extensive clinical registries and predictable service models. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape in which varied regulatory frameworks and reimbursement environments require adaptive market entry strategies; manufacturers often pursue targeted approvals and local partnerships to address fragmented HTA processes and diverse clinical practice patterns.

The Asia-Pacific region continues to show rapid clinical adoption in tertiary centers, propelled by investments in minimally invasive respiratory care and a growing base of trained interventional clinicians. In that context, price sensitivity and the need for scalable manufacturing solutions influence commercialization strategies, and regional partnerships or licensing arrangements can accelerate access to broader patient populations. Across these geographies, transitional factors such as local clinical training programs, reimbursement pathway clarity, and supply chain localization efforts shape adoption speed. Therefore, successful regional strategies combine robust clinical evidence, regulatory acumen, and distribution models tailored to the operational rhythms and procurement priorities of each territory.

Key company-level implications emphasizing how clinical evidence, manufacturing excellence, intellectual property, and collaborative partnerships determine competitive positioning in the lung stent arena

Competitive dynamics among leading companies center on differentiation through technological innovation, clinical evidence generation, and strategic collaborations that accelerate access and reimbursement. Market leaders invest heavily in iterative device refinement, securing regulatory approvals across multiple jurisdictions while building registries and post-marketing studies to demonstrate comparative performance. At the same time, smaller innovators carve niches by developing specialized stents or novel drug-elution platforms, and they frequently partner with larger manufacturers for distribution or co-development to scale commercialization efficiently. Intellectual property portfolios remain a critical asset, with patent strategies protecting key material formulations, scaffold architectures, and delivery mechanisms that underpin clinical differentiation.

In parallel, companies are placing greater emphasis on manufacturing excellence and quality system integration to meet intensified post-market scrutiny and to shorten time-to-replenishment in hospital supply chains. Strategic alliances with contract manufacturers and investments in near-market production capability have emerged as distinguishing capabilities for firms that can offer dependable lead times and regulatory compliance across regions. Additionally, firms that integrate digital tools-such as advanced imaging compatibility, procedure planning software, and outcomes-tracking platforms-enhance clinician adoption by lowering the learning curve and enabling data-driven post-procedural follow-up. Collectively, these competitive behaviors suggest that successful companies will be those that combine robust clinical data, scalable manufacturing, and value-added service offerings to meet evolving stakeholder expectations.

Actionable strategic recommendations that align product development, evidence programs, supply chain resilience, and commercial models to accelerate clinical adoption and market access

Industry leaders should adopt an integrated strategy that synchronizes product innovation, evidence generation, and supply chain resilience to capture clinical and commercial opportunities effectively. First, prioritize development pathways that align material selection and device architecture with clearly defined indications and patient cohorts to reduce regulatory complexity and enhance clinician uptake. Simultaneously, invest in early and sustained real-world evidence programs that complement pivotal studies, as continuous outcome capture strengthens reimbursement negotiations and supports iterative device improvement. Moreover, enhancing relationships with strategic suppliers and diversifying manufacturing footprints will mitigate tariff and logistics risks while shortening response times to clinical demand.

In addition, expand commercial models beyond product sales to include clinical training, procedural support, and digital outcomes tools that lower barriers to adoption in both ambulatory and hospital settings. Pursue targeted regional partnerships to navigate heterogeneous regulatory and reimbursement landscapes, and consider licensing or co-development arrangements to accelerate market entry where local clinical practice or price sensitivity requires adaptation. Finally, maintain a proactive regulatory engagement strategy that anticipates post-market surveillance expectations and addresses safety signals transparently. By executing these coordinated actions, leaders can strengthen their value propositions for clinicians, payers, and procurement organizations while positioning their portfolios for sustainable long-term adoption.

A transparent mixed-methods research approach combining expert interviews, document analysis, and data triangulation to validate clinical, technical, and commercial findings and identify evidence gaps

The research underlying this analysis employed a mixed-methods approach combining primary qualitative engagement and rigorous secondary review to ensure comprehensive insight into clinical, technical, and commercial dimensions. Primary efforts included structured interviews with interventional pulmonologists, thoracic surgeons, device developers, procurement officers, and regulatory specialists to capture firsthand perspectives on procedural needs, material performance, and purchasing criteria. These conversations informed hypotheses that were then tested through a targeted review of clinical literature, device registries, regulatory filings, and technology assessment reports to corroborate safety and performance themes emerging from stakeholder interviews.

Data synthesis relied on triangulation across sources to validate key findings and minimize single-source bias, with particular attention to device design characteristics, material science developments, and post-market surveillance trends. The methodology also incorporated analysis of supply chain vulnerabilities and policy shifts, using public trade and regulatory records to contextualize tariff impacts and manufacturing responses. Limitations include variability in practice patterns across regions and the evolving nature of clinical evidence for novel materials; consequently, where uncertainty exists, the analysis highlights areas requiring additional primary study or extended registry follow-up. Transparency in methodology allows readers to assess the strength of evidence and to identify gaps that warrant further investigation or targeted clinical research.

A concluding synthesis emphasizing that integrated evidence generation, manufacturing resilience, and collaborative commercial models will determine the future trajectory of lung stent adoption

The lung stent field stands at an inflection point where material innovation, procedural advances, and evolving procurement dynamics collectively influence which technologies will gain traction in clinical practice. Translating design improvements into measurable patient benefit requires coordinated investments in clinical evidence, manufacturing reliability, and post-market outcome capture. Moreover, recent policy shifts and supply chain pressures have underscored the operational importance of diversified sourcing and regulatory agility. As stakeholders navigate these complexities, those who integrate rigorous clinical data generation with adaptable manufacturing and targeted commercial strategies will be best positioned to deliver sustained clinical value and organizational growth.

In conclusion, the pathway to broader adoption depends not only on technical performance but also on demonstrable patient outcomes, seamless supply continuity, and alignment with the payment and procurement frameworks that govern health systems. Manufacturers, clinicians, and purchasers who collaborate on evidence standards, training, and lifecycle support can accelerate safe and effective use of lung stents across a widening range of indications and care settings, ultimately improving patient respiratory outcomes and procedural efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Stents Market, by Product Type

  • 8.1. Bioresorbable Stents
    • 8.1.1. Magnesium-Based
    • 8.1.2. PLLA-Based
  • 8.2. Drug-Eluting Stents
  • 8.3. Metallic Stents
  • 8.4. Polymer Stents
    • 8.4.1. Biodegradable
    • 8.4.2. Nondegradable

9. Lung Stents Market, by Indication

  • 9.1. Airway Obstruction
  • 9.2. Malacia
  • 9.3. Tracheobronchial Stenosis
  • 9.4. Tumor
    • 9.4.1. Benign Tumor
    • 9.4.2. Malignant Tumor

10. Lung Stents Market, by Material

  • 10.1. Nitinol
  • 10.2. Polymer-Based
    • 10.2.1. Poly-L-Lactic Acid
    • 10.2.2. Polycarbonate Urethane
  • 10.3. Stainless Steel

11. Lung Stents Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Lung Stents Market, by Distribution Channel

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Hospitals

13. Lung Stents Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Lung Stents Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Lung Stents Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Lung Stents Market

17. China Lung Stents Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Boston Scientific Corporation
  • 18.6. BVM Medical Limited
  • 18.7. Cook Medical LLC
  • 18.8. Medtronic plc
  • 18.9. Meril Life Sciences Pvt. Ltd
  • 18.10. Merit Medical Systems, Inc.
  • 18.11. Novatech SA
  • 18.12. Stening SRL
  • 18.13. Taewoong Medical Co., Ltd
  • 18.14. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUNG STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LUNG STENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LUNG STENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LUNG STENTS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG STENTS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LUNG STENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG STENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LUNG STENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES LUNG STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA LUNG STENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LUNG STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LUNG STENTS MARKET SIZE, BY MAGNESIUM-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LUNG STENTS MARKET SIZE, BY MAGNESIUM-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LUNG STENTS MARKET SIZE, BY MAGNESIUM-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LUNG STENTS MARKET SIZE, BY PLLA-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUNG STENTS MARKET SIZE, BY PLLA-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LUNG STENTS MARKET SIZE, BY PLLA-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LUNG STENTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LUNG STENTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LUNG STENTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LUNG STENTS MARKET SIZE, BY METALLIC STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LUNG STENTS MARKET SIZE, BY METALLIC STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LUNG STENTS MARKET SIZE, BY METALLIC STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUNG STENTS MARKET SIZE, BY POLYMER STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LUNG STENTS MARKET SIZE, BY POLYMER STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUNG STENTS MARKET SIZE, BY POLYMER STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LUNG STENTS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LUNG STENTS MARKET SIZE, BY BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUNG STENTS MARKET SIZE, BY BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LUNG STENTS MARKET SIZE, BY NONDEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUNG STENTS MARKET SIZE, BY NONDEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LUNG STENTS MARKET SIZE, BY NONDEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LUNG STENTS MARKET SIZE, BY AIRWAY OBSTRUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUNG STENTS MARKET SIZE, BY AIRWAY OBSTRUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LUNG STENTS MARKET SIZE, BY AIRWAY OBSTRUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUNG STENTS MARKET SIZE, BY MALACIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LUNG STENTS MARKET SIZE, BY MALACIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG STENTS MARKET SIZE, BY MALACIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LUNG STENTS MARKET SIZE, BY TRACHEOBRONCHIAL STENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG STENTS MARKET SIZE, BY TRACHEOBRONCHIAL STENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LUNG STENTS MARKET SIZE, BY TRACHEOBRONCHIAL STENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUNG STENTS MARKET SIZE, BY TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LUNG STENTS MARKET SIZE, BY TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUNG STENTS MARKET SIZE, BY TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG STENTS MARKET SIZE, BY BENIGN TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LUNG STENTS MARKET SIZE, BY BENIGN TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG STENTS MARKET SIZE, BY BENIGN TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LUNG STENTS MARKET SIZE, BY MALIGNANT TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUNG STENTS MARKET SIZE, BY MALIGNANT TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LUNG STENTS MARKET SIZE, BY MALIGNANT TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LUNG STENTS MARKET SIZE, BY NITINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUNG STENTS MARKET SIZE, BY NITINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LUNG STENTS MARKET SIZE, BY NITINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LUNG STENTS MARKET SIZE, BY POLYMER-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LUNG STENTS MARKET SIZE, BY POLYMER-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LUNG STENTS MARKET SIZE, BY POLYMER-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUNG STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LUNG STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUNG STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LUNG STENTS MARKET SIZE, BY POLYCARBONATE URETHANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUNG STENTS MARKET SIZE, BY POLYCARBONATE URETHANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LUNG STENTS MARKET SIZE, BY POLYCARBONATE URETHANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUNG STENTS MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LUNG STENTS MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUNG STENTS MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LUNG STENTS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LUNG STENTS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LUNG STENTS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LUNG STENTS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LUNG STENTS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LUNG STENTS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LUNG STENTS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LUNG STENTS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LUNG STENTS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LUNG STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LUNG STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LUNG STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LUNG STENTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LUNG STENTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LUNG STENTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LUNG STENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LUNG STENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LUNG STENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LUNG STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS LUNG STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA LUNG STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL LUNG STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. GCC LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 184. GCC LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 185. GCC LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 186. GCC LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GCC LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. G7 LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 214. G7 LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 215. G7 LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 216. G7 LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. G7 LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. NATO LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 224. NATO LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 225. NATO LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 226. NATO LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. NATO LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL LUNG STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES LUNG STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA LUNG STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA LUNG STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA LUNG STENTS MARKET SIZE, BY BIORESORBABLE STENTS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA LUNG STENTS MARKET SIZE, BY POLYMER STENTS, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA LUNG STENTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA LUNG STENTS MARKET SIZE, BY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA LUNG STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA LUNG STENTS MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA LUNG STENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA LUNG STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)